<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240032</url>
  </required_header>
  <id_info>
    <org_study_id>PM014</org_study_id>
    <nct_id>NCT00240032</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare injection skin (injection site) reactions when an
      antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections.
      Patients will be assigned (like a flip of a coin) to take either a placebo or an
      antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and
      physician will be unaware whether they are taking a placebo or antihistamine during the
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection Site Reaction</measure>
    <time_frame>5 weeks</time_frame>
    <description>Injection site reaction after taking antihistamine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Copaxone® with Zyrtec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Copaxone® with placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate injection with oral cetirizine hydrochloride</intervention_name>
    <description>Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet</description>
    <arm_group_label>Copaxone® with Zyrtec</arm_group_label>
    <other_name>Copaxone®, Zyrtec®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate with placebo</intervention_name>
    <description>Copaxone® injection 20 mg, oral placebo</description>
    <arm_group_label>Copaxone® with placebo</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18 years of age or older

          -  Diagnosis of RRMS

          -  Beginning or recently (within &lt; 3months) began self-injecting Copaxone®

        Exclusion Criteria:

          -  Taking any other immunomodulatory therapy in conjunction with Copaxone®

          -  Unable to perform subcutaneous self-injection

          -  Pregnant or trying to become pregnant, or breast feeding during the study

          -  Previously participated in this study or in another clinical trial in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MerriKay Oleen-Burkey, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mswatch.com</url>
    <description>For more information about Multiple Sclerosis</description>
  </link>
  <link>
    <url>http://www.tevaneuro.com</url>
    <description>For more information about Teva Neuroscience, Inc.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Smith, MD, VP Medical Affairs</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

